21results about How to "Reduced infarct volume" patented technology

The invention discloses a novel nano-drug Res (at) LDH and a preparation method and application thereof.Germanium-doped LDH powder and resveratrol are combined to obtain a nanoscale particle mixed material Res (at) LDH, electron paramagnetic resonance (EPR) tests show that both the germanium-doped LDH and the traditional drug resveratrol show excellent reactive oxygen species (ROS) removal characteristics, and the Res (at) LDH can be used for preparing a novel nano-drug Res (at) LDH. The nano-drug Res (at) LDH formed by combining the two has remarkable synergistic ROS removal efficiency which can reach 90%. Meanwhile, in-vivo biological distribution experiments show that the novel nano-drug Res (at) LDH has excellent blood-brain barrier permeability, enhances accumulation in brain tissues, improves neurological dysfunction, reduces infarct volume, shows strong antioxidant activity, and inhibits release of pro-inflammatory cytokines.

The invention discloses an application of a polypeptide in preparation of a medicine for preventing or treating cerebral apoplexy. The polypeptide comprises an amino acid sequence as shown in SEQ ID NO: 1. The N15 polypeptide expressed by the sequence can inhibit apoptosis and autophagy of damaged neurons by inhibiting expression of Tom20 and PARP proteins, promote expression of SYN-1 protein to promote a patient with ischemic cerebral apoplexy to recover learning, memory and cognitive functions, can comprehensively protect neuronal damage caused by ischemic cerebral apoplexy, can promote recovery of damaged nerve cells of an OGD model, and has a good application prospect. The polypeptide has an obvious protection effect on neuronal cells, the polypeptide is connected with a cell transmembrane carrier and can penetrate through a blood brain barrier to enter brain tissue to directly act on the neuronal cells, and an ischemic cerebral apoplexy animal model verifies that the polypeptide has an effect of treating cerebral apoplexy. Particularly, the cognitive ability and learning and memory ability of a mouse with cerebral arterial thrombosis can be recovered to a normal level, and a good treatment effect on cerebral arterial thrombosis is achieved.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a pyrazole carboxylic acid bornyl ester compound as well as a preparation method and application thereof. The invention provides a series of pyrazole carboxylic acid bornyl ester compounds with novel structures, namely compounds shown in a formula (I) or pharmaceutically acceptable salts thereof. The compound can play an excellent neuroprotective role in multiple ways of scavenging free radicals, protecting neuronal cells from being damaged and the like, and plays an important role in preparation of drugs for preventing or treating cerebral apoplexy, cardiovascular and cerebrovascular diseases and neurodegenerative diseases caused by excessive free radicals. # imgabs0 #

The application relates to the use of a TYK2 inhibitor, in particular a heterocyclic compound represented by the formula (I) or a pharmaceutically acceptable salt, solvate or isomer thereof in the preparation of a drug for treating or preventing ischemic stroke.

The invention discloses an edaravone homologue as well as a method and application thereof. The edaravone homologue has a structure shown in a formula (I), in the formula (I), R1 and R2 are substituent groups at any position on a benzene ring, and R1-R2 are the same or different and are independently selected from hydrogen or C1-C3 alkyl. Compared with edaravone, the edaravone homologue disclosed by the invention has the advantages that the oxidative stress level can be more effectively reduced, neuronal apoptosis is inhibited, and cerebral ischemia reperfusion injury is improved. # imgabs0 #

The invention discloses an application of RNF13 in preparation of a medicine for preventing or treating cerebral apoplexy, the expressed RNF13 has the effects of reducing infarct volume, protecting neurological functions, inhibiting neuroinflammation, reducing the number of dead nerve cells and inhibiting cerebral apoplexy diseases, and the RNF13 is used for preparing the medicine for preventing, relieving and / or treating the cerebral apoplexy diseases.

The invention belongs to the technical field of medicines, and provides application of polypeptide in preparation of a medicine for treating cerebral apoplexy. The amino acid sequence of the polypeptide is as follows: Ala-Glu-Pro-Val-Pro-Leu. The polypeptide has different degrees of significant improvement effects on death rate, neurobehavioral scoring and cerebral infarction volume of model rats, can significantly improve rat brain tissue hippocampal CA1 region vertebral cell injury, and also has significant improvement effects on brain microcirculation after bilateral carotid artery ligation of the model rats.

The present invention provides microglia-derived exosomes and a preparation method and application thereof. The present invention provides a preparation method of microglia-derived exosomes, the preparation method comprising: culturing microglia in a culture medium containing gardenia glycosides, ligustrazine and puerarin to secrete exosomes, thereby obtaining microglia-derived exosomes. The microglia-derived exosomes prepared by the present invention can reduce neuroinflammation, inhibit oxidative stress and ferroptosis, reduce cerebral infarction volume, improve ischemia-reperfusion neurological scores, and improve brain tissue pathological damage, and have a neuroprotective effect on cerebral ischemia-reperfusion injury.

The invention discloses a pyrazolone compound as well as a preparation method and application thereof. The pyrazolone compound has a structure as shown in a formula (I), in the formula (I), R1 and R2 are substituent groups at any position on a benzene ring, and R1-R2 are the same or different and are independently selected from hydrogen or C1-C6 alkyl. Compared with 3-methyl-1-phenyl-2-pyrazoline-5-ketone (EDA), the pyrazolone compound disclosed by the invention can be used for more effectively inhibiting oxidative stress, inhibiting neuronal apoptosis and improving cerebral ischemia reperfusion injury. # imgabs0 #

This invention relates to the field of biomedical technology, specifically disclosing a polypeptide and its application in the preparation of drugs for ischemic stroke. The amino acid sequence of the polypeptide is shown in SEQ ID NO. 1. This invention utilizes an in vivo tMCAO / R model and in vitro studies covering ischemic hypoxia (OGD) and neurotoxicity (MPP). + Multiple cell models of NL-PT, including those for cellular stress and hormonal stress (CORT), were used to reveal the application potential of the peptide NL-PT from multiple dimensions and levels. These results collectively demonstrate that NL-PT not only has a significant protective effect against the core pathological processes of ischemic stroke, but also exhibits broad-spectrum biological activity against various related injuries. In particular, its well-defined mechanism of anti-oxidative stress through scavenging reactive oxygen species (ROS) further highlights its multi-target intervention characteristics, providing solid and reliable experimental evidence for its development into a novel, multi-target therapeutic drug for ischemic stroke.

The application relates to the technical field of medicines, and particularly discloses a mitochondrion transfer promoter and application of the mitochondrion transfer promoter in preparation of medicines for preventing and treating post-CIRI mitochondrion dysfunction, wherein the active component of the promoter is decocted liquid of blue cloth and pyrola calliantha, and the mass ratio of the blue cloth to the pyrola calliantha is 2-4:1-2. The mitochondrion transfer promoter is prepared by decocting and extracting the blue cloth and the pyrola calliantha, animal experiments are conducted, it is found that the mitochondrion transfer promoter can significantly improve CIRI induced by cerebral middle artery ischemia-reperfusion, reduce a neurological function defect score, reduce a cerebral infarction volume, and it is proved by HE and Nissl staining that the mitochondrion transfer promoter can effectively improve neuron morphology and reduce neuron death. The mitochondrion transfer promoter can improve mitochondrion function, reduce oxidative stress, and enhance blood-brain barrier endothelial function, and has important clinical significance and practical value.

A use of and method for telaprevir in the preparation of a drug and a cytoprotective drug for treating ischemia / reperfusion injury. Telaprevir is used for the preparation of a drug for treating ischemia / reperfusion injury, in particular for treating myocardial cells and nerve cell damage, said drug having in particular a good protective effect on heart and cerebral ischemia / reperfusion (myocardial infarction and ischemic stroke), and can significantly alleviate heart and cerebral ischemia / reperfusion injury.

The invention provides application of strychnine nitric oxide in preparation of a medicine for preventing and treating cerebral arterial thrombosis and a composition for preventing and treating cerebral arterial thrombosis, and belongs to the technical field of medicines. The invention provides application of strychnine nitric oxide in preparation of a medicine for preventing and treating cerebral arterial thrombosis. According to the present invention, the strychnine nitrogen oxide retains the biological activity and the effect of strychnine, can be used for preventing and treating cerebral arterial thrombosis, has less toxicity than the strychnine, and can significantly improve cerebral arterial thrombosis neurological function impairment and reduce the infarct volume when the strychnine nitrogen oxide is applied to treatment of cerebral arterial thrombosis, such that the strychnine nitrogen oxide can be used for preventing and treating cerebral arterial thrombosis. The traditional Chinese medicine composition can be used for preventing and treating cerebral arterial thrombosis, reducing inflammatory cell infiltration of brain tissues, protecting the integrity of blood-brain barriers and adjusting tight junction proteins, has a potential effect of preventing and treating cerebral arterial thrombosis, has obvious curative effect advantages, and can improve the defects of the current clinical treatment technology for cerebral arterial thrombosis.

The invention discloses an application of white datura in preparation of a medicine for preventing and treating cerebral ischemia-reperfusion injury. The invention proposes and verifies that white datura can effectively prevent and treat ischemia reperfusion injury for the first time, including greatly reducing the volume of cerebral infarction caused by cerebral ischemia reperfusion; meanwhile, the neurological function impairment symptoms such as motor coordination and balance ability reduction, spatial learning and reference memory impairment and depression-like behaviors caused by cerebral ischemia reperfusion are remarkably improved, and a natural medicine with great application potential is provided for mechanism research, prevention and treatment of cerebral ischemia reperfusion injury.

The invention belongs to the technical field of ischemic stroke treatment, and discloses application of ULK1 possibly serving as a target spot for treating ischemic stroke. According to the invention, a photothrombotic stroke model is established, a ULK1 inhibitor SBI-0206965 (SBI), LYN1604 hydrochloride (LYN) and a ULK1 agonist are administered, and the ULK1 agonist is used for regulating the activity of ULK1 in vivo. Examples assess the outcome of sensory motor deficits, neuronal apoptosis, and microglia / macrophage activated neurological function. Immunofluorescence detection results show that ULK1 is mainly located in microglial cells in a post-ischemic infarction area of China. Upregulated ULK1 is treated by LYN, so that the infarct volume is remarkably reduced, the motor function is improved, and the increase of inflammatory microglial cells is promoted. In conclusion, the ULK1 promotes the repair of neurons and promotes the formation of 13 paths of anti-inflammatory microglial cell paths after ischemic injury.

The invention relates to the technical field of biological medicine, in particular to a compound preparation for treating focal brain tissue ischemia-reperfusion injury and application of the compound preparation, the mass ratio of dextroborneol to citicoline is 1: 5000-1: 15000, preferably 1: 10000, the combined medicine of the compound preparation further comprises an auxiliary agent, and the auxiliary agent is a mixture of dextroborneol and citicoline. The auxiliary agent comprises any one or a combination of at least two of a stabilizer, a diluent, a carrier, a fluidizing agent, a dissolution medium, an oxidizing agent and a PH regulator, and the focal brain tissue ischemia reperfusion related injury is at least one of encephaledema, cerebral infarction, inflammatory response, oxidative injury, brain function injury and brain tissue pathological injury. According to the invention, the dexhanol and the citicoline are quantitatively proportioned and combined, so that the pharmaceutical composition has a remarkable neuroprotective effect in relieving focal brain tissue ischemia-reperfusion injury, the effect of the pharmaceutical composition after combination is obviously superior to that of a single medicine, the use effect of the pharmaceutical composition is improved, and the pharmaceutical composition has a good clinical application prospect.

The invention discloses an application of ginsenoside Ro in preparation of a medicine for treating cerebral ischemia-reperfusion injury. According to the application disclosed by the invention, by preparing a middle cerebral artery occlusion / reperfusion (MCAO) mouse model, the ginsenoside Ro is found to be capable of reducing the cerebral infarction volume of the model mouse, improving the pathological injury of brain tissues and increasing the cerebral blood flow at the ischemic side. Meanwhile, the ginsenoside Ro up-regulates the expression of brain tissue tight junction proteins ZO-1 and Occludin, inhibits the expression of matrix metalloproteinase MMP-9 / 2, reduces the leakage amount of Evans blue, and improves the blood brain barrier (BBB) dysfunction. Besides, by preparing an oxygen glucose deprivation / reperfusion (OGD / R) induced mouse brain microvascular endothelial cell line 3 (bEnd.3) cell model, it is found that the ginsenoside Ro can improve the damage of the barrier function of the bEnd.3 cell induced by the OGD / R, it is proved that the ginsenoside Ro can be used for the novel medical application of treating the cerebral arterial thrombosis, and the ginsenoside Ro has a wide application prospect.

The present application provides the use of aucubin or the combination of aucubin and ACA in the preparation of a medicament for treating ischemic brain injury, in particular acute cerebral ischemia-reperfusion injury. The present application first discovers that aucubin or the combination of aucubin and ACA can increase the blood flow of the ischemic side after ischemic brain injury in mice; significantly reduce the cerebral infarction volume; improve the cognitive and motor function of mice after ischemic brain injury; reduce the degree of injury caused by cerebral ischemia, significantly improve the degree of neuronal necrosis of brain tissue after ischemia; significantly increase the survival rate of HT22 cells after oxygen-glucose deprivation and reperfusion injury, reduce intracellular Ca 2+ fluorescence intensity, and inhibit cell apoptosis.

The invention provides a trilobatin-containing composition as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The trilobatin-containing composition provided by the invention comprises trilobatin, squalene, an oil phase and an emulsifier, the composition comprises the following components in percentage by mass: 0.1-5% of trilobatin, 1.3-7% of squalene, 4-10% of an oil phase and 1-3% of an emulsifier, the composition is a microemulsion. The trilobatin and squalene are mixed according to a proper ratio, so that the distribution of the trilobatin in brain tissues can be improved, the solubility can be enhanced, the stability can be improved, the volume of cerebral infarction caused by cerebral ischemia or reperfusion injury can be reduced, the neurological function score can be improved, the level of inflammatory factors in a body can be reduced, and the trilobatin and squalene composition has good safety and stability. On the other hand, the preparation method of the composition provided by the invention has the characteristics of simple process and mild conditions, is beneficial to large-scale production, and has wide application space and market prospect.

The invention relates to the technical field of medicines, in particular to application of euglena in preparation of a product for prevention and / or adjuvant therapy of cerebral arterial thrombosis. Experiments prove that by means of supplementation of the euglena, the infarct volume is remarkably reduced, the neurological function defect is relieved, the synaptic plasticity of mouse hippocampus is enhanced, and the neuroprotective effect of the euglena is related to improvement of the integrity of intestinal barriers, reduction of systemic and neuroinflammation and regulation of intracerebral insulin signal channels; and the euglena can favorably change the composition of intestinal microbiota and promote the production of short-chain fatty acids. In conclusion, the euglena can relieve the cerebral arterial thrombosis through the enterocerebral axis, so that the euglena can be well used for developing related products for prevention and / or adjuvant therapy of the cerebral arterial thrombosis.

This invention belongs to the field of biomedical technology and discloses a methylene blue-fingolimod prodrug based on hypochlorous acid activation, its preparation method, and its application. Fingolimod and methylene blue, which has hypochlorous acid scavenging and neuroprotective functions, are bonded together via a hypochlorous acid-sensitive thioether bridge. This design cleverly utilizes the abnormally high concentration of hypochlorous acid within the lesion as "molecular scissors," achieving precise activation of the prodrug at the target site and synergistic release of both drugs. This not only endows fingolimod with targeted noise reduction and enhanced efficacy but also simultaneously implements a combined attack of "detoxification" and "anti-inflammation," thereby more thoroughly breaking the damage cascade and providing a novel synergistic solution for stroke treatment.